Small molecule PET tracer for Lewy bodies in the brain for diagnosing Parkinson’s Disease or other Lewy body related diseases.
- PET tracer to enable quantification of α-Syn.
- Improves diagnosis of Parkinson’s disease.
- Allows for earlier treatment.
Parkinson’s disease is a neurodegenerative disorder that causes movement issues such as tremors, slowness, limb rigidity and balance problems. In the brains of patients with Parkinson’s, there are abnormal protein deposits called Lewy bodies that consist of α-Syn. There are currently no blood or laboratory tests consistent in effectively diagnosing the disease. Current diagnosis relies on medical history, a neurological examination, and ruling out other diseases. An imaging tracer that quantifies α-Syn aggregation in vivo, would greatly improve clinical diagnosis.
Scientists at Emory have found a PET tracer that enables the quantification of α-Syn aggregates in Lewy bodies and Lewy neuritis. The PET tracers have been evaluated against Tau and A-beta and they show high selectivity for α-Syn. These tracers may improve diagnosis of Parkinson’s disease as well as enable earlier treatment.
In vivo imaging studies in mice are currently underway.